Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

3 of Eli Lilly's Top Drugs Grew by Over 40% in Q2. Trulicity Wasn't One of Them.

TheMotleyFool

0 0

3 of Eli Lilly's Top Drugs Grew by Over 40% in Q2. Trulicity Wasn't One of Them.: https://g.foolcdn.com/editorial/images/743965/a-doctor-looking-at-a-tablet-with-another-person.jpg

Eli Lilly (NYSE: LLY) has been a top growth stock in the healthcare industry for years. The company's vast pipeline and diverse business have allowed it to continue to find ways to grow -- and Trulicity has been a key growth catalyst for the business in recent years.

But now, other drugs are growing at much faster rates today and could soon eclipse Trulicity in revenue. Let's see what this could all mean for Eli Lilly and its shareholders.

Diabetes drug Trulicity generated more than $7.4 billion in revenue for Eli Lilly last year, accounting for more than one-quarter of the company's top line, which totaled $28.5 billion.

Source Fool.com

Like: 0

LLY

Share